Details of the Drug

General Information of Drug (ID: DMKVWGE)

• Drug Name: Dexbrompheniramine
• Synonyms: Dexbromfeniramina; Dexbrompheniraminum; Ilvin; Parabromodylamine; D-Brompheniramine; Dexbromfeniramina [INN-Spanish]; Dexbrompheniramine [INN:BAN]; Dexbrompheniraminum [INN-Latin]; N,N-Dimethyl-(3-(4-bromphenyl)-3-(2-pyridyl)propyl)amin; (3-p-Bromphenyl-3-pyrid-2'-ylpropyl)dimethylamin; (3S)-3-(4-bromophenyl)-N,N-dimethyl-3-(pyridin-2-yl)propan-1-amine; (3S)-3-(4-bromophenyl)-N,N-dimethyl-3-pyridin-2-ylpropan-1-amine; (S)-(+)-brompheniramine; (S)-brompheniramine

Indication

Disease Entry	ICD 11	Status	REF
Hay fever	CA08.00	Approved	[1], [2], [3]

• Therapeutic Class: Antihistamines
• Drug Type: Small molecular drug
• #Ro5 Violations (Lipinski): 0:
  Molecular Weight (mw); 319.24
  Topological Polar Surface Area (xlogp); 3.5
  Rotatable Bond Count (rotbonds); 5
  Hydrogen Bond Donor Count (hbonddonor); 0
  Hydrogen Bond Acceptor Count (hbondacc); 2
• ADMET Property:
  Absorption: The drug is well absorbed from the gastrointestinal tract [4]
  Half-life: The concentration or amount of drug in body reduced by one-half in 25 hours [5]
  Metabolism: The drug is metabolized via the hepatic [4]
• Chemical Identifiers:
  Formula: C16H19BrN2
  IUPAC Name: (3S)-3-(4-bromophenyl)-N,N-dimethyl-3-pyridin-2-ylpropan-1-amine
  Canonical SMILES: CN(C)CC[C@@H](C1=CC=C(C=C1)Br)C2=CC=CC=N2
  InChI: InChI=1S/C16H19BrN2/c1-19(2)12-10-15(16-5-3-4-11-18-16)13-6-8-14(17)9-7-13/h3-9,11,15H,10,12H2,1-2H3/t15-/m0/s1
  InChIKey: ZDIGNSYAACHWNL-HNNXBMFYSA-N
• Cross-matching ID:
  PubChem CID: 16960
  ChEBI ID: CHEBI:59269
  CAS Number: 132-21-8
  DrugBank ID: DB00405
  TTD ID: D02WIW
  ACDINA ID: D00186

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Histamine H1 receptor (H1R)	TTTIBOJ	HRH1_HUMAN	Antagonist	[6]

Molecular Expression Atlas of This Drug

• The Studied Disease: Hay fever
• ICD Disease Classification: CA08.00

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Histamine H1 receptor (H1R)	DTT	HRH1	6.74E-01	0.13	0.43

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Dexbrompheniramine

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Disease	REF
Chlorpheniramine	DM5URA2	Moderate	Additive anticholinergic effects by the combination of Dexbrompheniramine and Chlorpheniramine.	Vasomotor/allergic rhinitis [CA08]	[15]
Triprolidine	DM7SWIA	Moderate	Additive anticholinergic effects by the combination of Dexbrompheniramine and Triprolidine.	Vasomotor/allergic rhinitis [CA08]	[15]
Methdilazine	DMAUHQX	Moderate	Additive anticholinergic effects by the combination of Dexbrompheniramine and Methdilazine.	Vasomotor/allergic rhinitis [CA08]	[15]
Carbinoxamine	DMCT31R	Moderate	Additive anticholinergic effects by the combination of Dexbrompheniramine and Carbinoxamine.	Vasomotor/allergic rhinitis [CA08]	[15]
Trimeprazine	DMEMV9D	Moderate	Additive anticholinergic effects by the combination of Dexbrompheniramine and Trimeprazine.	Vasomotor/allergic rhinitis [CA08]	[16]
Brompheniramine	DMFOVSD	Moderate	Additive anticholinergic effects by the combination of Dexbrompheniramine and Brompheniramine.	Vasomotor/allergic rhinitis [CA08]	[15]
Acrivastine	DMTIGA0	Moderate	Additive anticholinergic effects by the combination of Dexbrompheniramine and Acrivastine.	Vasomotor/allergic rhinitis [CA08]	[15]
Azatadine	DMZ80SB	Moderate	Additive anticholinergic effects by the combination of Dexbrompheniramine and Azatadine.	Vasomotor/allergic rhinitis [CA08]	[15]

Coadministration of a Drug Treating the Disease Different from Dexbrompheniramine (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Scopolamine	DMOM8AL	Moderate	Additive anticholinergic effects by the combination of Dexbrompheniramine and Scopolamine.	Addictive disorder [6C50-6C5Z]	[15]
Mepyramine	DMB4SFH	Moderate	Additive anticholinergic effects by the combination of Dexbrompheniramine and Mepyramine.	Allergic/hypersensitivity disorder [4A80-4A8Z]	[16]
Phenyltoloxamine	DMKAEQW	Moderate	Additive anticholinergic effects by the combination of Dexbrompheniramine and Phenyltoloxamine.	Allergic/hypersensitivity disorder [4A80-4A8Z]	[16]
Tripelennamine	DMZBU15	Moderate	Additive anticholinergic effects by the combination of Dexbrompheniramine and Tripelennamine.	Allergic/hypersensitivity disorder [4A80-4A8Z]	[15]
Memantine	DMD9WSC	Moderate	Additive anticholinergic effects by the combination of Dexbrompheniramine and Memantine.	Alzheimer disease [8A20]	[15]
Galantamine	DMEO794	Moderate	Antagonize the effect of Dexbrompheniramine when combined with Galantamine.	Alzheimer disease [8A20]	[17]
Rivastigmine	DMG629M	Moderate	Antagonize the effect of Dexbrompheniramine when combined with Rivastigmine.	Alzheimer disease [8A20]	[17]
Donepezil	DMIYG7Z	Moderate	Antagonize the effect of Dexbrompheniramine when combined with Donepezil.	Alzheimer disease [8A20]	[17]
Hydroxyzine	DMF8Y74	Moderate	Additive anticholinergic effects by the combination of Dexbrompheniramine and Hydroxyzine.	Anxiety disorder [6B00-6B0Z]	[15]
Promazine	DMZAL7W	Moderate	Additive anticholinergic effects by the combination of Dexbrompheniramine and Promazine.	Appearance/behaviour symptom [MB23]	[15]
Desipramine	DMT2FDC	Moderate	Additive anticholinergic effects by the combination of Dexbrompheniramine and Desipramine.	Attention deficit hyperactivity disorder [6A05]	[15]
Linezolid	DMGFPU2	Moderate	Additive CNS depression effects by the combination of Dexbrompheniramine and Linezolid.	Bacterial infection [1A00-1C4Z]	[18]
Cariprazine	DMJYDVK	Moderate	Additive anticholinergic effects by the combination of Dexbrompheniramine and Cariprazine.	Bipolar disorder [6A60]	[15]
Loperamide	DMOJZQ9	Moderate	Additive antimotility effects by the combination of Dexbrompheniramine and Loperamide.	Bowel habit change [ME05]	[19]
Acetylcholine	DMDF79Z	Moderate	Antagonize the effect of Dexbrompheniramine when combined with Acetylcholine.	Cataract [9B10]	[20]
Umeclidinium	DM4E8O9	Moderate	Additive anticholinergic effects by the combination of Dexbrompheniramine and Umeclidinium.	Chronic obstructive pulmonary disease [CA22]	[21]
Tiotropium	DMFDC0Q	Moderate	Additive anticholinergic effects by the combination of Dexbrompheniramine and Tiotropium.	Chronic obstructive pulmonary disease [CA22]	[21]
Revefenacin	DMMP5SI	Moderate	Additive anticholinergic effects by the combination of Dexbrompheniramine and Revefenacin.	Chronic obstructive pulmonary disease [CA22]	[21]
Olopatadine	DMKMWQG	Moderate	Additive CNS depression effects by the combination of Dexbrompheniramine and Olopatadine.	Conjunctiva disorder [9A60]	[22]
Ethanol	DMDRQZU	Moderate	Additive CNS depression effects by the combination of Dexbrompheniramine and Ethanol.	Cystitis [GC00]	[22]
Trimipramine	DM1SC8M	Moderate	Additive anticholinergic effects by the combination of Dexbrompheniramine and Trimipramine.	Depression [6A70-6A7Z]	[15]
Cyclobenzaprine	DM1YBRM	Moderate	Additive anticholinergic effects by the combination of Dexbrompheniramine and Cyclobenzaprine.	Depression [6A70-6A7Z]	[15]
Imipramine	DM2NUH3	Moderate	Additive anticholinergic effects by the combination of Dexbrompheniramine and Imipramine.	Depression [6A70-6A7Z]	[15]
Nortriptyline	DM4KDYJ	Moderate	Additive anticholinergic effects by the combination of Dexbrompheniramine and Nortriptyline.	Depression [6A70-6A7Z]	[15]
Isocarboxazid	DMAF1NB	Moderate	Additive CNS depression effects by the combination of Dexbrompheniramine and Isocarboxazid.	Depression [6A70-6A7Z]	[18]
Tranylcypromine	DMGB5RE	Moderate	Additive CNS depression effects by the combination of Dexbrompheniramine and Tranylcypromine.	Depression [6A70-6A7Z]	[18]
OPC-34712	DMHG57U	Moderate	Additive anticholinergic effects by the combination of Dexbrompheniramine and OPC-34712.	Depression [6A70-6A7Z]	[15]
Phenelzine	DMHIDUE	Moderate	Additive CNS depression effects by the combination of Dexbrompheniramine and Phenelzine.	Depression [6A70-6A7Z]	[18]
Clomipramine	DMINRKW	Moderate	Additive anticholinergic effects by the combination of Dexbrompheniramine and Clomipramine.	Depression [6A70-6A7Z]	[15]
Amoxapine	DMKITQE	Moderate	Additive anticholinergic effects by the combination of Dexbrompheniramine and Amoxapine.	Depression [6A70-6A7Z]	[15]
Doxepin	DMPI98T	Moderate	Additive anticholinergic effects by the combination of Dexbrompheniramine and Doxepin.	Depression [6A70-6A7Z]	[15]
Maprotiline	DMPWB7T	Moderate	Additive anticholinergic effects by the combination of Dexbrompheniramine and Maprotiline.	Depression [6A70-6A7Z]	[15]
Esketamine	DMVU687	Moderate	Additive CNS depression effects by the combination of Dexbrompheniramine and Esketamine.	Depression [6A70-6A7Z]	[23]
Hyoscyamine	DM804UR	Moderate	Additive anticholinergic effects by the combination of Dexbrompheniramine and Hyoscyamine.	Digestive system disease [DE2Z]	[15]
Mepenzolate	DM8YU2F	Moderate	Additive anticholinergic effects by the combination of Dexbrompheniramine and Mepenzolate.	Digestive system disease [DE2Z]	[15]
Oxybutynine	DMJPBAX	Moderate	Additive anticholinergic effects by the combination of Dexbrompheniramine and Oxybutynine.	Discovery agent [N.A.]	[15]
Meclizine	DMS7T13	Moderate	Additive anticholinergic effects by the combination of Dexbrompheniramine and Meclizine.	Dizziness and giddiness [MB48]	[15]
Zonisamide	DM0DTF7	Major	Increased risk of hyperpyrexia by the combination of Dexbrompheniramine and Zonisamide.	Epilepsy/seizure [8A61-8A6Z]	[24]
Diphenhydramine	DMKQTBA	Moderate	Additive anticholinergic effects by the combination of Dexbrompheniramine and Diphenhydramine.	Episodic vestibular syndrome [AB31]	[15]
Solifenacin	DMG592Q	Moderate	Additive anticholinergic effects by the combination of Dexbrompheniramine and Solifenacin.	Functional bladder disorder [GC50]	[15]
Tolterodine	DMSHPW8	Moderate	Additive anticholinergic effects by the combination of Dexbrompheniramine and Tolterodine.	Functional bladder disorder [GC50]	[15]
Darifenacin	DMWXLYZ	Moderate	Additive anticholinergic effects by the combination of Dexbrompheniramine and Darifenacin.	Functional bladder disorder [GC50]	[15]
Propantheline	DM2EN6G	Moderate	Additive anticholinergic effects by the combination of Dexbrompheniramine and Propantheline.	Gastric ulcer [DA60]	[15]
Isoflurophate	DMBSK7X	Moderate	Antagonize the effect of Dexbrompheniramine when combined with Isoflurophate.	Glaucoma [9C61]	[20]
Brimonidine	DMQLT4N	Moderate	Additive CNS depression effects by the combination of Dexbrompheniramine and Brimonidine.	Glaucoma [9C61]	[25]
Pilocarpine	DMV9ADG	Moderate	Antagonize the effect of Dexbrompheniramine when combined with Pilocarpine.	Glaucoma [9C61]	[20]
Procarbazine	DMIK367	Moderate	Additive CNS depression effects by the combination of Dexbrompheniramine and Procarbazine.	Hodgkin lymphoma [2B30]	[18]
Belladonna	DM2RBWK	Moderate	Additive anticholinergic effects by the combination of Dexbrompheniramine and Belladonna.	Infectious gastroenteritis/colitis [1A40]	[15]
Amantadine	DMS3YE9	Moderate	Additive anticholinergic effects by the combination of Dexbrompheniramine and Amantadine.	Influenza [1E30-1E32]	[26]
ITI-007	DMUQ1DO	Moderate	Additive anticholinergic effects by the combination of Dexbrompheniramine and ITI-007.	Insomnia [7A00-7A0Z]	[15]
Clidinium	DMUMQZ0	Moderate	Additive anticholinergic effects by the combination of Dexbrompheniramine and Clidinium.	Irritable bowel syndrome [DD91]	[15]
Dicyclomine	DMZSDGX	Moderate	Additive anticholinergic effects by the combination of Dexbrompheniramine and Dicyclomine.	Irritable bowel syndrome [DD91]	[15]
Physostigmine	DM2N0TO	Moderate	Antagonize the effect of Dexbrompheniramine when combined with Physostigmine.	Lips/oral mucosa miscellaneous disorder [DA02]	[17]
Allopregnanolone	DMNLHAC	Moderate	Additive CNS depression effects by the combination of Dexbrompheniramine and Allopregnanolone.	Mental/behavioural/neurodevelopmental disorder [6E20-6E8Z]	[27]
Lasmiditan	DMXLVDT	Moderate	Additive CNS depression effects by the combination of Dexbrompheniramine and Lasmiditan.	Migraine [8A80]	[28]
Flibanserin	DM70DTN	Moderate	Additive CNS depression effects by the combination of Dexbrompheniramine and Flibanserin.	Mood disorder [6A60-6E23]	[29]
Thalidomide	DM70BU5	Moderate	Additive CNS depression effects by the combination of Dexbrompheniramine and Thalidomide.	Multiple myeloma [2A83]	[30]
Phenindamine	DMDTC7R	Moderate	Additive anticholinergic effects by the combination of Dexbrompheniramine and Phenindamine.	Nasopharyngitis [CA00]	[15]
Dimenhydrinate	DM264B3	Moderate	Additive anticholinergic effects by the combination of Dexbrompheniramine and Dimenhydrinate.	Nausea/vomiting [MD90]	[15]
Prochlorperazine	DM53SRA	Moderate	Additive anticholinergic effects by the combination of Dexbrompheniramine and Prochlorperazine.	Nausea/vomiting [MD90]	[15]
Promethazine	DM6I5GR	Moderate	Additive anticholinergic effects by the combination of Dexbrompheniramine and Promethazine.	Nausea/vomiting [MD90]	[15]
Cyclizine	DM9G7BS	Moderate	Additive anticholinergic effects by the combination of Dexbrompheniramine and Cyclizine.	Nausea/vomiting [MD90]	[15]
Apraclonidine	DMO4PVE	Moderate	Additive CNS depression effects by the combination of Dexbrompheniramine and Apraclonidine.	Optic nerve disorder [9C40]	[25]
Dextropropoxyphene	DM23HCX	Major	Additive CNS depression effects by the combination of Dexbrompheniramine and Dextropropoxyphene.	Pain [MG30-MG3Z]	[31]
Flavoxate	DMKV4NL	Moderate	Additive anticholinergic effects by the combination of Dexbrompheniramine and Flavoxate.	Pain [MG30-MG3Z]	[15]
Biperiden	DME78OA	Moderate	Additive anticholinergic effects by the combination of Dexbrompheniramine and Biperiden.	Parkinsonism [8A00]	[15]
Orphenadrine	DMW542E	Moderate	Additive anticholinergic effects by the combination of Dexbrompheniramine and Orphenadrine.	Parkinsonism [8A00]	[15]
Methylscopolamine	DM5VWOB	Moderate	Additive anticholinergic effects by the combination of Dexbrompheniramine and Methylscopolamine.	Peptic ulcer [DA61]	[15]
Levomepromazine	DMIKFEL	Moderate	Additive anticholinergic effects by the combination of Dexbrompheniramine and Levomepromazine.	Psychotic disorder [6A20-6A25]	[15]
Fluphenazine	DMIT8LX	Moderate	Additive anticholinergic effects by the combination of Dexbrompheniramine and Fluphenazine.	Psychotic disorder [6A20-6A25]	[15]
Triflupromazine	DMKFQJP	Moderate	Additive anticholinergic effects by the combination of Dexbrompheniramine and Triflupromazine.	Psychotic disorder [6A20-6A25]	[15]
Cyproheptadine	DM92AH3	Moderate	Additive anticholinergic effects by the combination of Dexbrompheniramine and Cyproheptadine.	Rheumatoid arthritis [FA20]	[15]
Quetiapine	DM1N62C	Moderate	Additive anticholinergic effects by the combination of Dexbrompheniramine and Quetiapine.	Schizophrenia [6A20]	[15]
Mesoridazine	DM2ZGAN	Moderate	Additive anticholinergic effects by the combination of Dexbrompheniramine and Mesoridazine.	Schizophrenia [6A20]	[15]
Thioridazine	DM35M8J	Moderate	Additive anticholinergic effects by the combination of Dexbrompheniramine and Thioridazine.	Schizophrenia [6A20]	[15]
Aripiprazole	DM3NUMH	Moderate	Additive anticholinergic effects by the combination of Dexbrompheniramine and Aripiprazole.	Schizophrenia [6A20]	[15]
Iloperidone	DM6AUFY	Moderate	Additive anticholinergic effects by the combination of Dexbrompheniramine and Iloperidone.	Schizophrenia [6A20]	[15]
Paliperidone	DM7NPJS	Moderate	Additive anticholinergic effects by the combination of Dexbrompheniramine and Paliperidone.	Schizophrenia [6A20]	[15]
Loxapine	DM8AI9U	Moderate	Additive anticholinergic effects by the combination of Dexbrompheniramine and Loxapine.	Schizophrenia [6A20]	[15]
Haloperidol	DM96SE0	Moderate	Additive anticholinergic effects by the combination of Dexbrompheniramine and Haloperidol.	Schizophrenia [6A20]	[15]
Perphenazine	DMA4MRX	Moderate	Additive anticholinergic effects by the combination of Dexbrompheniramine and Perphenazine.	Schizophrenia [6A20]	[15]
Molindone	DMAH70G	Moderate	Additive anticholinergic effects by the combination of Dexbrompheniramine and Molindone.	Schizophrenia [6A20]	[15]
Chlorpromazine	DMBGZI3	Moderate	Additive anticholinergic effects by the combination of Dexbrompheniramine and Chlorpromazine.	Schizophrenia [6A20]	[15]
Thiothixene	DMDINC4	Moderate	Additive anticholinergic effects by the combination of Dexbrompheniramine and Thiothixene.	Schizophrenia [6A20]	[15]
Trifluoperazine	DMKBYWI	Moderate	Additive anticholinergic effects by the combination of Dexbrompheniramine and Trifluoperazine.	Schizophrenia [6A20]	[15]
Risperidone	DMN6DXL	Moderate	Additive anticholinergic effects by the combination of Dexbrompheniramine and Risperidone.	Schizophrenia [6A20]	[15]
Asenapine	DMSQZE2	Moderate	Additive anticholinergic effects by the combination of Dexbrompheniramine and Asenapine.	Schizophrenia [6A20]	[15]
Pimozide	DMW83TP	Moderate	Additive anticholinergic effects by the combination of Dexbrompheniramine and Pimozide.	Schizophrenia [6A20]	[15]
Tizanidine	DMR2IQ4	Moderate	Additive CNS depression effects by the combination of Dexbrompheniramine and Tizanidine.	Tonus and reflex abnormality [MB47]	[32]
Atropine	DMEN6X7	Moderate	Additive anticholinergic effects by the combination of Dexbrompheniramine and Atropine.	Unspecific substance harmful effect [NE6Z]	[15]

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Mannitol	E00103	6251	Diluent; Flavoring agent; Lyophilization aid; Plasticizing agent; Tonicity agent
Stearic acid	E00079	5281	Emulsifying agent; Solubilizing agent; Viscosity-controlling agent; lubricant
Sucralose	E00370	71485	Flavoring agent
Brushite	E00392	104805	Diluent
Carmellose sodium	E00625	Not Available	Disintegrant
Magnesium stearate	E00208	11177	lubricant
Silicon dioxide	E00670	Not Available	Anticaking agent; Opacifying agent; Viscosity-controlling agent
Xylitol	E00136	6912	Coating agent; Diluent; Emollient; Flavoring agent; Humectant

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Dexbrompheniramine 1 mg tablet	1 mg	Chewable Tablet	Oral
Dexbrompheniramine 2 mg tablet	2 mg	Oral Tablet	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7588).
• [2] FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 089116.
• [3] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [4] FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014 Sep 1;20(17):4436-41.
• [5] Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
• [6] H2 histaminergic control of inhibition of eating induced by intragastric NaCl in rats. Physiol Behav. 1998 Aug;65(1):105-13.
• [7] Cloning and pharmacological characterization of a fourth histamine receptor (H(4)) expressed in bone marrow. Mol Pharmacol. 2001 Mar;59(3):420-6.
• [8] Clinical research of Ibudilast on treating the steroid resistant allergic rhinitis. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2009 Jan;23(2):63-6.
• [9] Intact cell binding for in vitro prediction of sedative and non-sedative histamine H1-receptor antagonists based on receptor internalization. J Pharmacol Sci. 2008 May;107(1):66-79.
• [10] Update on prescription and over-the-counter histamine inverse agonists in rhinitis therapy. Curr Allergy Asthma Rep. 2009 Mar;9(2):140-8.
• [11] Central effects of cinnarizine: restricted use in aircrew. Aviat Space Environ Med. 2002 Jun;73(6):570-4.
• [12] Novel therapeutic usage of low-dose doxepin hydrochloride. Expert Opin Investig Drugs. 2007 Aug;16(8):1295-305.
• [13] Influence of epinastine hydrochloride, an H1-receptor antagonist, on the function of mite allergen-pulsed murine bone marrow-derived dendritic cell... Mediators Inflamm. 2009;2009:738038.
• [14] Examining the tolerability of the non-sedating antihistamine desloratadine: a prescription-event monitoring study in England. Drug Saf. 2009;32(2):169-79.
• [15] Cohen MA, Alfonso CA, Mosquera M. Development of urinary retention during treatment with clozapine and meclizine [published correction appears in Am J Psychiatry 1994 Jun;151(6):952]. Am J Psychiatry. 1994;151(4):619-620. [PMID: 8147469]
• [16] Kulik AV, Wilbur R "Delirium and stereotypy from anticholinergic antiparkinson drugs." Prog Neuropsychopharmacol Biol Psychiatry 6 (1982): 75-82. [PMID: 7202232]
• [17] Beers MH, Ouslander JG, Rollingher I, Reuben DB, Brooks J, Beck JC "Explicit criteria for determining inappropriate medication use in nursing home residents." Arch Intern Med 151 (1991): 1825-32. [PMID: 1888249]
• [18] Canadian Pharmacists Association.
• [19] Eronen M, Putkonen H, Hallikainen T, Vartiainen H "Lethal gastroenteritis associated with clozapine and loperamide." Am J Psychiatry 160 (2003): 2242-2243. [PMID: 14638602]
• [20] Multum Information Services, Inc. Expert Review Panel.
• [21] Cole JM, Sheehan AH, Jordan JK "Concomitant use of ipratropium and tiotropium in chronic obstructive plmonary disease." Ann Pharmacother 46 (2012): 1717-21. [PMID: 23170031]
• [22] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7. [PMID: 3725002]
• [23] Cerner Multum, Inc. "Australian Product Information.".
• [24] Product Information. Zonegran (zonisamide) Elan Pharmaceuticals, S. San Francisco, CA.
• [25] Product Information. Alphagan (brimonidine ophthalmic). Allergan Inc, Irvine, CA.
• [26] Postma JU, van Tilburg W "Visual hallucinations and delirium during treatment with amantadine (Symmetrel)." J Am Geriatr Soc 23 (1975): 212-5. [PMID: 123540]
• [27] Product Information. Zulresso (brexanolone). Sage Therapeutics, Inc., Cambridge, MA.
• [28] Product Information. Reyvow (lasmiditan). Lilly, Eli and Company, Indianapolis, IN.
• [29] Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
• [30] Product Information. Thalomid (thalidomide). Celgene Corporation, Warren, NJ.
• [31] Hansen BS, Dam M, Brandt J, et al "Influence of dextropropoxyphene on steady state serum levels and protein binding of three anti-epileptic drugs in man." Acta Neurol Scand 61 (1980): 357-67. [PMID: 6998251]
• [32] Product Information. Zanaflex (tizanidine). Acorda Therapeutics, Hawthorne, NY.